论文部分内容阅读
目的分析研究尿激酶静脉溶栓治疗急性心肌梗死的临床疗效及安全性。方法将74例急性心肌梗死患者随机分为观察组和对照组各37例,对照组采用常规治疗,观察组患者在对照组治疗基础上,实施尿激酶静脉溶栓治疗。观察两组患者临床疗效及不良反应。结果观察组冠脉再通率显著高于对照组(P<0.05);观察组心力衰竭发生率、梗死后心绞痛发生率和死亡率均低于对照组(P<0.05)。结论早期尿激酶静脉溶栓治疗能够显著提高急性心肌梗死冠状动脉再通率、降低心绞痛发生,能够有效地降低患者的病死率,临床效果显著,值得推广。
Objective To study the clinical efficacy and safety of intravenous thrombolysis with urokinase in the treatment of acute myocardial infarction. Methods A total of 74 acute myocardial infarction patients were randomly divided into observation group and control group, 37 cases in each group. The control group was treated by conventional therapy. The observation group was treated with intravenous thrombolysis of urokinase on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were observed. Results The rate of coronary recanalization in the observation group was significantly higher than that in the control group (P <0.05). The incidence of heart failure, the incidence of post-infarction angina pectoris and mortality in the observation group were lower than those in the control group (P <0.05). Conclusion Early intravenous urokinase thrombolytic therapy can significantly improve the rate of recanalization of coronary artery in patients with acute myocardial infarction and reduce angina pectoris, which can effectively reduce the mortality of patients. The clinical effect is significant and worthy of promotion.